Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines
Vita-Salute San Raffaele University · Istituti di Ricovero e Cura a Carattere Scientifico · +27 more institutions
Abstract
MRI has improved the diagnostic work-up of multiple sclerosis, but inappropriate image interpretation and application of MRI diagnostic criteria contribute to misdiagnosis. Some diseases, now recognized as conditions distinct from multiple sclerosis, may satisfy the MRI criteria for multiple sclerosis (e.g. neuromyelitis optica spectrum disorders, Susac syndrome), thus making the diagnosis of multiple sclerosis more challenging, especially if biomarker testing (such as serum anti-AQP4 antibodies) is not informative. Improvements in MRI technology contribute and promise to better define the typical features of multiple sclerosis lesions (e.g. juxtacortical and periventricular location, cortical involvement).…
Citation impact
- FWCI
- 35.35
- Percentile
- 100%
- References
- 127
Authors
17- MFMassimo FilippiCorresponding
Vita-Salute San Raffaele University, Istituti di Ricovero e Cura a Carattere Scientifico, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
- PPPaolo Preziosa
Vita-Salute San Raffaele University, Istituti di Ricovero e Cura a Carattere Scientifico, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
- BBBrenda Banwell
Children's Hospital of Philadelphia, University of Pennsylvania
- FBFrederik Barkhof
Vrije Universiteit Brussel, Amsterdam Neuroscience, Amsterdam University Medical Centers, University College London, Vrije Universiteit Amsterdam
- OCOlga Ciccarelli
Queen Mary University of London, National Institute for Health and Care Research, National Hospital for Neurology and Neurosurgery, University College London
Topics & keywords
- Multiple sclerosis
- Neuromyelitis optica
- Medicine
- Magnetic resonance imaging
- McDonald criteria
- Medical diagnosis
- Pathology
- Radiology
- Good health and well-being
Funding
- NMNational Multiple Sclerosis Society
- GGlaxoSmithKline
- SSanofi
- BBiogen
- TPTeva Pharmaceutical Industries
- APAlexion Pharmaceuticals
- CCelgene
- FIFondazione Italiana Sclerosi Multipla
- BBioClinica
- IPInternational Progressive MS Alliance
- NINational Institute for Health and Care Research
- MSMultiple Sclerosis Society
- UOUniversity of Oxford
- BHBayer HealthCare
- RTRosetrees Trust
- DFDeutsche Forschungsgemeinschaft
- MDMinistero della Salute
- IIXICO
- MPMedDay Pharmaceuticals
- NPNovartis Pharma
- H2Horizon 2020 Framework Programme
- CPChugai Pharmaceutical
- SGSanofi Genzyme
- MRMedical Research CouncilAwards: MR/S026088/1, MR/M009106/1
- NINational Institute of Neurological Disorders and Stroke